Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWNYIE)

Drug Name
Bemarituzumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Gastric adenocarcinoma 2B72 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMWNYIE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-2 (FGF2) TTGKIED FGF2_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Fibroblast growth factor-2 (FGF2) DTT FGF2 4.933 4.94 4.221 2.766
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Gastric adenocarcinoma
ICD Disease Classification 2B72
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor-2 (FGF2) DTT FGF2 6.36E-03 0.05 0.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03694522) A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)